title: Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.
abstract: The NRAS and BRAF genes are frequently mutated in melanoma, suggesting that the NRAS-BRAF-MEK-ERK signaling pathway is an important target for therapy. Two classes of drugs, one targeting activated BRAF and one targeting MEK, are currently undergoing clinical evaluation. We have analysed the NRAS and BRAF mutational status of a series of 44 early passage lines developed from New Zealand patients with metastatic melanoma. 41% of the lines analysed had BRAF mutations, 23% had NRAS mutations, and 36% had neither. We then determined IC50 values (drug concentrations for 50% growth inhibition) for CI-1040, a commonly used inhibitor of MEK kinase; trametinib, a clinical agent targeting MEK kinase; and vemurafenib, an inhibitor of mutant BRAF kinase. Cell lines with activating BRAF mutations were significantly more sensitive to vemurafenib than lines with NRAS mutations or lines lacking either mutation (p < 0.001). IC50 values for CI-1040 and trametinib were strongly correlated (r = 0.98) with trametinib showing ~100-fold greater potency. Cell lines sensitive to vemurafenib were also sensitive to CI-1040 and trametinib, but there was no relationship between IC50 values and NRAS mutation status. A small number of lines lacking a BRAF mutation were sensitive to CI-1040 but resistant to vemurafenib. We used western blotting to investigate the effect on ERK phosphorylation of CI-1040 in four lines, of vemurafenib in two lines and of trametinib in two lines. The results support the view that MEK inhibitors might be combined with BRAF inhibitors in the treatment of melanomas with activated BRAF. The high sensitivity to trametinib of some lines with wildtype BRAF status also suggests that MEK inhibitors could have a therapeutic effect against some melanomas as single agents.
authors: Department of Obstetrics and Gynaecology, The University of Auckland Auckland, New Zealand ; Auckland Cancer Society Research Centre, The University of Auckland Auckland, New Zealand.
authors: Clare J
authors: CJ
authors: Stones
authors: Ji Eun
authors: JE
authors: Kim
authors: Wayne R
authors: WR
authors: Joseph
authors: Euphemia
authors: E
authors: Leung
authors: Elaine S
authors: ES
authors: Marshall
authors: Graeme J
authors: GJ
authors: Finlay
authors: Andrew N
authors: AN
authors: Shelling
authors: Bruce C
authors: BC
authors: Baguley
keywords: BRAF; ERK; MEK; NRAS; melanoma treatment; mitogen-activated protein kinase pathway; trametinib; vemurafenib
references: Nature. 2006 Jan 19;439(7074):358-62
references: 16273091
references: Cancer Res. 2008 Aug 1;68(15):6145-53
references: 18676837
references: N Engl J Med. 2010 Aug 26;363(9):809-19
references: 20818844
references: N Engl J Med. 2012 Jul 12;367(2):107-14
references: 22663011
references: BMC Cancer. 2012 Apr 04;12:141
references: 22475322
references: Biochem Soc Trans. 2007 Nov;35(Pt 5):1329-33
references: 17956344
references: Cancer Res. 2009 May 15;69(10):4286-93
references: 19401449
references: ANZ J Surg. 2010 May;80(5):312-6
references: 20557503
references: Melanoma Res. 2006 Dec;16(6):471-8
references: 17119447
references: Cancer Genet. 2011 Sep;204(9):477-85
references: 22018269
references: Nature. 2010 Dec 16;468(7326):968-72
references: 21107320
references: Cell. 2010 Jan 22;140(2):209-21
references: 20141835
references: Eur J Cancer. 1994;30A(9):1370-6
references: 7999427
references: Curr Pharm Des. 2004;10(16):1907-14
references: 15180527
references: Mol Cancer Ther. 2012 May;11(5):1143-54
references: 22402123
references: Lancet Oncol. 2012 Aug;13(8):782-9
references: 22805292
references: J Natl Cancer Inst. 1992 Mar 4;84(5):340-5
references: 1738186
references: Cancer Causes Control. 2006 Feb;17(1):21-7
references: 16411049
references: J Biol Chem. 2004 Apr 16;279(16):15719-22
references: 14970221
references: Nature. 2002 Jun 27;417(6892):949-54
references: 12068308
references: Nat Genet. 2007 Mar;39(3):347-51
references: 17293865
references: Nucleic Acids Res. 1975 Mar;2(3):383-9
references: 236548
references: Nat Protoc. 2009;4(7):1073-81
references: 19561590
references: J Carcinog. 2004 Mar 26;3:6
references: 15046639
references: Br J Cancer. 2009 Feb 10;100(3):431-5
references: 19156138